Study reverses current thought on treatment of cirrhosis

June 19, 2014, Mayo Clinic

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients. Metformin is usually discontinued once cirrhosis is diagnosed because of concerns about an increased risk of adverse effects associated with this treatment in patients with liver impairment. The Mayo Clinic study was recently published in Hepatology.

Cirrhosis is scarring of the liver caused by forms of liver diseases, such as chronic viral hepatitis, chronic alcohol abuse and non-alcoholic fatty liver disease. This condition is the consequence of damage done to the liver over many years. As cirrhosis progresses, more and more scar tissue forms, impeding proper liver functions.

Metformin is used to treat high blood sugar levels caused by . This type of diabetes works in two ways. First, it inhibits the pancreas from producing sufficient insulin, which normally regulates the movement of sugar, glucose, into cells. Glucose is the body's main source of fuel. Second, in type 2 diabetes the liver, muscle, and fat tissues become more resistant to the effects of insulin. The combination of decreased insulin production and insulin resistance results in an abnormally high level of glucose in the blood.

Obesity-related can lead to liver inflammation and cirrhosis, and also is associated with diabetes. Therefore, type 2 diabetes is found in 37 percent of cirrhotic , five times more than in those without cirrhosis.

In the study, a sample of 172 patients continued taking , while another 78 individuals discontinued metformin after cirrhosis diagnosis. Patients who continued metformin as part of their treatment had a significantly longer median survival than those who stopped taking the drug. During the follow up, it was discovered that none of the patients taking metformin developed lactic acidosis, which was thought to be a common side effect of the drug in patients with cirrhosis.

"Our study suggests that metformin can be used safely in . Diabetic patients who take metformin to control their can continue taking metformin after cirrhosis diagnosis, if there is no specific contradiction," says gastroenterologist Lewis Roberts, M.B., Ch.B., Ph.D., senior author of the study.

With the potential implications for a major change in current clinical practice, the researchers plan to collaborate with more institutions and use nationwide databases to further validate the beneficial effects of metformin, according to Xiaodan Zhang, D.D.S., co-author of the study.

Explore further: African-Americans respond better to first-line diabetes drug than whites

More information: "Continuation of metformin use after a diagnosis of cirrhosis significantly improved survival of patients with diabetes." Xiaodan Zhang, William S. Harmsen, Teresa A. Mettler, W. Ray Kim, Rosebud O. Roberts, Terry M. Therneau, Lewis R. Roberts and Roongruedee Chaiteerakij. Hepatology. 2014 May 3. DOI: 10.1002/hep.27199

Related Stories

African-Americans respond better to first-line diabetes drug than whites

June 12, 2014
African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine ...

Team unlocks secrets of diabetes drug: How and why metformin needs to interact with insulin to be effective

November 3, 2013
About 120 million people around the world with Type 2 diabetes – and two million in Canada – take the drug metformin to control their disease.

Study: Most-used diabetes drug works in different way than previously thought

January 6, 2013
A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, ...

Metformin usually adequate for control of gestational diabetes

August 18, 2013
(HealthDay)—Among women with gestational diabetes mellitus, those receiving metformin achieve lower mean glucose levels compared with those receiving insulin, but some require supplemental insulin therapy, according to ...

Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven

June 17, 2014
Canagliflozin (trade name: Invokana) has been approved since November 2013 as monotherapy and in various combination therapies for adults with type 2 diabetes mellitus when diet and exercise alone do not provide adequate ...

Common diabetes drugs may carry risk, study suggests

September 26, 2013
(HealthDay)—Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says.

Recommended for you

A new theory on reducing cardiovascular disease risk in binge drinkers

January 23, 2018
A new study shows that binge drinkers have increased levels of a biomarker molecule—microRNA-21—that may contribute to poor vascular function.

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.